Estradiol/drospirenone

Estradiol/drospirenone (E2/DRSP), sold under the brand name Angeliq, is a combination of estradiol (E2), an estrogen, and drospirenone (DRSP), a progestin, antimineralocorticoid, and antiandrogen, which is used in menopausal hormone therapy, specifically the treatment of menopausal syndrome and osteoporosis, in postmenopausal women.[1][2] It is taken by mouth and contains 0.5 to 1 mg E2 and 0.25 to 0.5 mg DRSP per tablet.[1] The medication was approved in the United States in 2005.[1] It is marketed widely throughout the world.[3][4]

Estradiol/drospirenone
Estradiol
Drospirenone
Combination of
EstradiolEstrogen
DrospirenoneProgestogen; Progestin; Antimineralocorticoid; Antiandrogen
Clinical data
Trade namesAngeliq
Other namesE2/DRSP; BAY-864891
Routes of
administration		By mouth
Drug classEstrogen; Progestin; Progestogen; Antimineralocorticoid; Antiandrogen
Legal status
Legal status

See also

References
  1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021355s003lbl.pdf
  2. https://adisinsight.springer.com/drugs/800014148
  3. https://www.drugs.com/international/drospirenone.html
  4. https://www.drugs.com/international/angeliq.html


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.